CollPlant Biotechnologies (CLGN) Depreciation & Amortization (CF) (2018 - 2025)
CollPlant Biotechnologies (CLGN) posted Depreciation & Amortization (CF) of $216000.0 for Q4 2025, down 3.14% on a QoQ basis from $223000.0 in Q3 2025, and down 10.74% year-over-year from $242000.0 in Q4 2024.
CollPlant Biotechnologies (CLGN) Depreciation & Amortization (CF) (2018 - 2025) Analysis & Trends
CollPlant Biotechnologies' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $216000.0 for Q4 2025.
- Quarterly Depreciation & Amortization (CF) fell 10.74% year-over-year to $216000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $668000.0 (down 11.87% YoY) and the FY2025 annual result came in at $912000.0, down 12.14% from the prior year.
- Depreciation & Amortization (CF) was $216000.0 for Q4 2025 at CollPlant Biotechnologies, down from $223000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $294000.0 in Q4 2022 and bottomed at $173000.0 in Q1 2021.
- A 5-year average of $245105.3 and a median of $255000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 45.81% — and 2024, when it decreased 14.79%.
- CollPlant Biotechnologies' Depreciation & Amortization (CF) stood at $224000.0 in 2021, then soared by 31.25% to $294000.0 in 2022, then retreated by 3.4% to $284000.0 in 2023, then declined by 14.79% to $242000.0 in 2024, then decreased by 10.74% to $216000.0 in 2025.
- Business Quant data shows CLGN's Depreciation & Amortization (CF) at $216000.0 in Q4 2025, $223000.0 in Q3 2025, and $229000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.20 Mn |
| 10 | CollPlant Biotechnologies | 4.63 Mn | 4.63 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 216,000.00 |
| Dec 31, 2025 | 216,000.00 |
| Sep 30, 2025 | 223,000.00 |
| Sep 30, 2025 | 223,000.00 |
| Jun 30, 2025 | 229,000.00 |
| Jun 30, 2025 | 229,000.00 |
| Dec 31, 2024 | 242,000.00 |
| Dec 31, 2024 | 242,000.00 |
| Sep 30, 2024 | 255,000.00 |
| Sep 30, 2024 | 255,000.00 |
| Jun 30, 2024 | 261,000.00 |
| Jun 30, 2024 | 261,000.00 |
| Mar 31, 2024 | 280,000.00 |
| Mar 31, 2024 | 280,000.00 |
| Dec 31, 2023 | 284,000.00 |
| Dec 31, 2023 | 284,000.00 |
| Sep 30, 2023 | 272,000.00 |
| Sep 30, 2023 | 272,000.00 |
| Jun 30, 2023 | 266,000.00 |
| Jun 30, 2023 | 266,000.00 |